The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
FGFR: Proof-of-concept study of AZD4547 in patients with FGFR1 or FGFR2 amplified tumours.
Elizabeth Catherine Smyth
No relevant relationships to disclose
Nicholas C. Turner
Consultant or Advisory Role - AstraZeneca; EOS GmbH; Novartis; SERVIER
Research Funding - AstraZeneca
Sanjay Popat
Consultant or Advisory Role - AstraZeneca (U)
Shethah Morgan
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Kate Owen
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Angela Gillbanks
No relevant relationships to disclose
Vikram Kumar Jain
No relevant relationships to disclose
David Cunningham
Consultant or Advisory Role - Amgen (U); Roche (U)
Research Funding - Amgen; Celgene; Novartis; Roche; Sanofi